May 2016- Volume 12, Issue 5

May 2016

In this Issue

Business & Government Policy

Bioclinica and ArisGlobal seek to transform pharmacovigilance

Bioclinica and ArisGlobal seek to transform pharmacovigilance

In an effort to improve the pharmacovigilance model, they look to comprehensive cloud solutions to help lower costs, raise quality

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Patent Docs: Interference will decide CRISPR patent rights

Patent Docs: Interference will decide CRISPR patent rights

The process begins to see who has the patent rights regarding CRISPR technology

Innovation impact

Innovation impact

U.S. ranks first in ITIF analysis of policy impact on life-sciences innovation

Change on the way for GSK

Change on the way for GSK

CEO announces retirement ahead of strong Q1 financial report; speculation begins about future directions

Biggest pharma combo becomes biggest bust

Biggest pharma combo becomes biggest bust

Rule changes by Treasury Department mean trouble for any U.S. companies attempting inversion deals in near term

Discovery

Johnson Matthey and Domainex collaborate to enhance discovery and development services

Johnson Matthey and Domainex collaborate to enhance discovery and development services

Johnson Matthey and Domainex Ltd. have announced a collaboration to provide integrated small-molecule pharmaceutical discovery and development services

Insulin signaling could link Alzheimer’s and diabetes

Insulin signaling could link Alzheimer’s and diabetes

Mouse models of Alzheimer’s disease were found to have impaired insulin signaling and insulin resistance, a precursor of diabetes

A first for CRISPR?

A first for CRISPR?

Scientists use CRISPR-Cas9 to target RNA in live cells

Protein p62 puts the brakes on inflammation

Protein p62 puts the brakes on inflammation

Findings could have implications for gout, atherosclerosis, type 2 diabetes, macular degeneration, Alzheimer’s disease and cancer

CRISPR for the liver

CRISPR for the liver

Regeneron and Intellia announce collaboration to discover and develop CRISPR/Cas therapeutics

Preclinical

End in sight for omadacycline

End in sight for omadacycline

Paratek makes headway towards new broad-spectrum antibiotic

Preclinical positivity for Prothena

Preclinical positivity for Prothena

Antibodies against misfolded transthyretin successfully bind misfolded proteins, recognize amyloid deposits in vitro

Bioprinting frontier

Bioprinting frontier

Organovo offers human tissue with 3D printing to enable complex experiments

Mitochondria-based therapeutics against aging

Mitochondria-based therapeutics against aging

CohBar announces preclinical proof-of-principle publication for SHLP mitochondrial-derived peptides

DBV announces data on targeted regulatory T cell induction during epicutaneous immunotherapy

DBV announces data on targeted regulatory T cell induction during epicutaneous immunotherapy

DBV Technologies today announced the publication of experimental data in mice in Cellular & Molecular Immunology characterizing the response of regulatory T cell to allergen-specific immunotherapy intended for the treatment of food allergies

Research & Development

Strategically going digital

Strategically going digital

Collaboration between Dassault and Inserm is designed to advance the use of ‘virtual trials’

Identification key to reproducibility

Identification key to reproducibility

Antibody Registry project gains momentum, new commercial partners

Looking ahead with PepSee

Looking ahead with PepSee

Zealand, BioSolveIT unveil software tool for therapeutic peptide research and development

Shooting for three strikes not to be out

Shooting for three strikes not to be out

SRI and Stanford to explore new molecular target for treatment of triple negative breast cancer

IU to offer data science courses using real clinical trial data

IU to offer data science courses using real clinical trial data

Indiana University will team up with Eli Lilly and Co. to offer one of the country’s first data sciences courses employing real-world clinical trial data

Clinical Trials

BL-8040 clears Phase 2 safety trial

BL-8040 clears Phase 2 safety trial

BioLineRx shares top-line results for its AML drug candidate

Depression deterrent

Depression deterrent

Minerva-Janssen joint development drug for MDD gets high marks in clinical trials

Genocea shares data on GEN-003 for genital herpes

Genocea shares data on GEN-003 for genital herpes

Immunotherapy shows sustained reduction of viral shedding rate and durable impact on clinical disease 12 months post-dosing

Out of the starting gate

Out of the starting gate

A roundup of clinical trial startups and initial breakthroughs

Prader-Willi progress

Prader-Willi progress

Pivotal Phase 3 study examines safety and efficacy of novel obesity therapeutic

Insulin with the quickness

Insulin with the quickness

Adocia and Lilly announce positive Phase 1b results for ultra-rapid BioChaperone Lispro

Diagnostics

Translating signatures

Translating signatures

HalioDx, NanoString Technologies to collaborate on novel gene expression assays in immuno-oncology

Rheonix scores ‘positive’ with fast HIV test

Rheonix scores ‘positive’ with fast HIV test

Microfluidic system and assay can simultaneously detect HIV antibodies and viral RNA

Protagen identifies biomarkers in prostate cancer

Protagen identifies biomarkers in prostate cancer

The protein biomarkers in prostate cancer represent potential drug targets supporting novel strategies in precision medicine

Avant and Amarantus Diagnostics to combine operations with Theranostics Health

Avant and Amarantus Diagnostics to combine operations with Theranostics Health

Avant Diagnostics Inc. and Amarantus Diagnostics Inc. recently announced that the companies have jointly entered into a letter of intent for Avant to acquire assets and certain liabilities of Theranostics Health Inc.

A new PATH for eliminating tropical diseases

A new PATH for eliminating tropical diseases

PATH, SD/Alere announce commercial availability of diagnostic tools for two neglected tropical diseases

Contract Services

A ‘triple win’

A ‘triple win’

NovAliX and FEI partner up to provide Cryo-EM to biopharma

Robust rebuilding

Robust rebuilding

Vetter groundbreaking is a major element of investment strategy

Crown makes oncology, cardiovascular and metabolic strides

Crown makes oncology, cardiovascular and metabolic strides

Crown strengthens immuno-oncology capabilities with HuGEMM and acquires PreClinOmics to expand cardio and metabolic disease portfolio

Q&A

Q&A with Geert Cauwenbergh of RXi Pharmaceuticals: Talking RNAi with RXi

Q&A with Geert Cauwenbergh of RXi Pharmaceuticals: Talking RNAi with RXi

The CEO of RXi Pharmaceuticals discusses the role of RNAi in general and in the advancement of his own company’s pipeline

Commentary

Guest Commentary: Individualized medicine vs. precision medicine

Guest Commentary: Individualized medicine vs. precision medicine

Personalized medicine, or precision medicine, isn't really as personalized or precise as many think or hope, relying more on population data than personalized data. Researchers in Finland, Sweden and Spain have modified ex-vivo testing of cancer cells with significant results that may offer an approach far more “personalized” than traditional precision medicine and perhaps provide a missing link between genomics-based mutation determination and clinical efficacy.

Guest Commentary: Data visualization--New directions or just familiar routes?

Guest Commentary: Data visualization--New directions or just familiar routes?

There is a risk that visualizations could end up being used to confirm or justify our own hypotheses and biases, but could data visualizations bring to light patterns in our data, drive new hypotheses and show us things we weren’t expecting?

Out of order: A story about anecdotes

Out of order: A story about anecdotes

When it comes to anecdotes vs. evidence, people often latch on to highly touted 'remedies' in the news and social media feeds that are often more rumor or hype than actual promise. However, even in the anecdotes, we sometimes find the beginning of wisdom that leads to development and clinical testing of potential therapeutics.

Editor's Focus

The ironic agonies of pain relief

The ironic agonies of pain relief

We keep trying to find ways to make it harder for people to abuse opioids. Perhaps we should be working harder to find new ways to treat intractable pain.

Feature

Show Preview: ISSCR 2016--Stem cells in San Francisco

Show Preview: ISSCR 2016--Stem cells in San Francisco

Following a couple of times outside the United States, ISSCR brings its annual meeting on stem cell research to Northern California’s Bay Area
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue  

• Volume 17 • Issue 6 • June 2021

June 2021

June 2021 issue